{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-105987","form_type":"8-K","ticker":null,"cik":"0001260990","company_name":"Oncternal Therapeutics, Inc.","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.413641+00:00","generated_at":"2026-05-31T05:10:08.431058+00:00","sec_items":["2.05","5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Oncternal cuts 37% workforce, discontinues two clinical trials, explores strategic alternatives","bullets":["Workforce reduction of ~10 employees (37%) to preserve cash; severance charges of ~$1.0M expected in Q3 2024.","CMO Salim Yazji to depart effective October 1, 2024, with severance benefits.","Discontinues ONCT-534 (prostate cancer) after interim Phase 1 showed no clinically meaningful PSA improvement in 20 patients.","Discontinues ONCT-808 (CAR T for B-cell lymphoma); had complete metabolic response but one death at highest dose.","Company will cease all product development and pursue strategic alternatives including sale, merger, or asset licensing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-105987","json":"https://secwatch.observer/filing/0000950170-24-105987.json","markdown":"https://secwatch.observer/filing/0000950170-24-105987.md","text":"https://secwatch.observer/filing/0000950170-24-105987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/0000950170-24-105987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/onct-20240911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:10:08.431058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e9e1e9e31","claim":"Salim Yazji departed as Chief Medical Officer at Oncternal Therapeutics, Inc..","evidence_excerpt":"Salim Yazji, M.D. will cease serving as Chief Medical Officer, to be effective as of October 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/0000950170-24-105987-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will cease serving"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"497667cd63c62b505d97ff9ff32eaf3ed9ff9b18","claim":"Oncternal Therapeutics, Inc. announced a restructuring with charges of approximately $1.0 million (approximately 10 employees, constituting approximately 37% of Oncternal’s workforce).","evidence_excerpt":"Oncternal currently estimates that it will incur charges associated with the workforce reduction of approximately $1.0 million primarily related to employee severance payments, benefits and related termination costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024105987/0000950170-24-105987-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.0 million"},{"label":"Headcount","value":"approximately 10 employees, constituting approximately 37% of Oncternal’s workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}